AR070430A1 - Inhibidores del receptor de quimioquinas cxcr3 - Google Patents
Inhibidores del receptor de quimioquinas cxcr3Info
- Publication number
- AR070430A1 AR070430A1 ARP090100561A ARP090100561A AR070430A1 AR 070430 A1 AR070430 A1 AR 070430A1 AR P090100561 A ARP090100561 A AR P090100561A AR P090100561 A ARP090100561 A AR P090100561A AR 070430 A1 AR070430 A1 AR 070430A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- independently
- optionally substituted
- membered
- substituted
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 title 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 abstract 2
- 102000009410 Chemokine receptor Human genes 0.000 abstract 2
- 108050000299 Chemokine receptor Proteins 0.000 abstract 2
- 125000003368 amide group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2973808P | 2008-02-19 | 2008-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070430A1 true AR070430A1 (es) | 2010-04-07 |
Family
ID=40527535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100561A AR070430A1 (es) | 2008-02-19 | 2009-02-18 | Inhibidores del receptor de quimioquinas cxcr3 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8268828B2 (enExample) |
| EP (1) | EP2262784B1 (enExample) |
| JP (1) | JP2011512412A (enExample) |
| KR (1) | KR20100123835A (enExample) |
| CN (1) | CN102007108A (enExample) |
| AR (1) | AR070430A1 (enExample) |
| AU (1) | AU2009215643A1 (enExample) |
| BR (1) | BRPI0908815A2 (enExample) |
| CA (1) | CA2715557A1 (enExample) |
| CL (1) | CL2009000368A1 (enExample) |
| CO (1) | CO6241113A2 (enExample) |
| CR (1) | CR11604A (enExample) |
| DO (1) | DOP2010000254A (enExample) |
| EC (1) | ECSP10010409A (enExample) |
| IL (1) | IL207597A0 (enExample) |
| MA (1) | MA32191B1 (enExample) |
| MX (1) | MX2010008397A (enExample) |
| NI (1) | NI201000132A (enExample) |
| NZ (1) | NZ587380A (enExample) |
| PE (1) | PE20091576A1 (enExample) |
| RU (1) | RU2010138577A (enExample) |
| SV (1) | SV2010003648A (enExample) |
| TW (1) | TW200948791A (enExample) |
| WO (1) | WO2009105435A1 (enExample) |
| ZA (1) | ZA201005314B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20091576A1 (es) | 2008-02-19 | 2009-11-05 | Sanofi Aventis | DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3 |
| EP2424840B1 (en) | 2009-04-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Cxcr3 receptor antagonists |
| WO2011084985A1 (en) * | 2010-01-07 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Cxcr3 receptor antagonists |
| KR101251788B1 (ko) | 2010-12-06 | 2013-04-08 | 기아자동차주식회사 | 차량 연비 정보 단말표시 시스템 및 그 방법 |
| CA2834199C (en) * | 2011-07-18 | 2020-01-07 | Merck Patent Gmbh | Benzamides as allosteric modulators of the fsh receptor |
| EP2601950A1 (en) | 2011-12-06 | 2013-06-12 | Sanofi | Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists |
| US9409897B2 (en) * | 2012-01-10 | 2016-08-09 | Merck Patent Gmbh | Benzamide derivatives as modulators of the follicle stimulating hormone |
| CA2861020C (en) | 2012-02-02 | 2018-07-17 | Actelion Pharmaceuticals Ltd | 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives and their use as cxcr3 receptor modulators |
| EP2666769A1 (en) | 2012-05-23 | 2013-11-27 | Sanofi | Substituted B-amino acid derivatives as CXCR3 receptor antagonist |
| ES2671323T3 (es) | 2013-07-22 | 2018-06-06 | Idorsia Pharmaceuticals Ltd | Derivados 1¿(piperazin¿1¿il)¿2¿([1,2,4]triazol¿1¿il)¿etanona |
| AR099789A1 (es) | 2014-03-24 | 2016-08-17 | Actelion Pharmaceuticals Ltd | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina |
| EP3193600A4 (en) * | 2014-09-10 | 2018-05-23 | Epizyme, Inc. | Smyd inhibitors |
| PL3245203T3 (pl) | 2015-01-15 | 2019-05-31 | Idorsia Pharmaceuticals Ltd | Pochodne hydroksyalkilopiperazyny jako modulatory receptora cxcr3 |
| AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
| WO2018183145A1 (en) * | 2017-03-26 | 2018-10-04 | Takeda Pharmaceutical Company Limited | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6 |
| CN115974766B (zh) * | 2023-01-04 | 2025-05-16 | 中国药科大学 | N-苄基-3-苯基酰胺类衍生物、包含其的药物组合物及其应用 |
| CN116410159B (zh) * | 2023-06-09 | 2023-08-22 | 济南国鼎医药科技有限公司 | 一种恩曲替尼中间体的制备方法及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2052541A5 (enExample) | 1969-06-13 | 1971-04-09 | Takeda Chemical Industries Ltd | |
| US3840556A (en) | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
| US6124319A (en) | 1997-01-21 | 2000-09-26 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
| US6469002B1 (en) | 2001-04-19 | 2002-10-22 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
| US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| GB0203994D0 (en) | 2002-02-20 | 2002-04-03 | Celltech R&D Ltd | Chemical compounds |
| US20050272936A1 (en) | 2002-06-03 | 2005-12-08 | Axten Jeffrey M | Imidazolium cxcr3 inhibitors |
| US6734659B1 (en) | 2002-06-13 | 2004-05-11 | Mykrolis Corporation | Electronic interface for use with dual electrode capacitance diaphragm gauges |
| CN101146793A (zh) * | 2005-02-16 | 2008-03-19 | 先灵公司 | 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物 |
| JP2008530220A (ja) | 2005-02-16 | 2008-08-07 | シェーリング コーポレイション | Ｃｘｃｒ３アンタゴニスト活性を有する、ピラジニルで置換されたピペラジン−ピペリジン |
| EP1856097B1 (en) | 2005-02-16 | 2012-07-11 | Schering Corporation | Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
| WO2007002742A1 (en) * | 2005-06-28 | 2007-01-04 | Pharmacopeia, Inc. | Substituted [1,4]-diazepanes as cxcr3 antagonists and their use in the treatment of inflammatory disorders |
| US7781437B2 (en) | 2005-10-11 | 2010-08-24 | Schering Corporation | Substituted heterocyclic compounds with CXCR3 antagonist activity |
| EP1957076A2 (en) | 2005-11-29 | 2008-08-20 | Merck & Co., Inc. | Thiazole derivatives as cxcr3 receptor modulators |
| PE20071144A1 (es) | 2006-03-21 | 2008-01-10 | Schering Corp | COMPUESTOS HETEROCICLICOS DE PIRIDINA SUSTITUIDA COMO ANTAGONISTAS DEL RECEPTOR 3 DE a-QUIMIOCINA (CXCR3) |
| KR20090043512A (ko) | 2006-07-14 | 2009-05-06 | 쉐링 코포레이션 | Ｃｘｃｒ3 길항제 활성을 갖는 헤테로사이클릭 치환된 피페라진 화합물 |
| PE20091576A1 (es) | 2008-02-19 | 2009-11-05 | Sanofi Aventis | DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3 |
-
2009
- 2009-02-17 PE PE2009000232A patent/PE20091576A1/es not_active Application Discontinuation
- 2009-02-18 AU AU2009215643A patent/AU2009215643A1/en not_active Abandoned
- 2009-02-18 AR ARP090100561A patent/AR070430A1/es not_active Application Discontinuation
- 2009-02-18 MX MX2010008397A patent/MX2010008397A/es not_active Application Discontinuation
- 2009-02-18 EP EP09711984.6A patent/EP2262784B1/en active Active
- 2009-02-18 CN CN2009801138321A patent/CN102007108A/zh active Pending
- 2009-02-18 KR KR1020107018467A patent/KR20100123835A/ko not_active Withdrawn
- 2009-02-18 RU RU2010138577/04A patent/RU2010138577A/ru not_active Application Discontinuation
- 2009-02-18 CL CL2009000368A patent/CL2009000368A1/es unknown
- 2009-02-18 JP JP2010547712A patent/JP2011512412A/ja active Pending
- 2009-02-18 BR BRPI0908815A patent/BRPI0908815A2/pt not_active IP Right Cessation
- 2009-02-18 CA CA2715557A patent/CA2715557A1/en not_active Abandoned
- 2009-02-18 NZ NZ587380A patent/NZ587380A/en not_active IP Right Cessation
- 2009-02-18 WO PCT/US2009/034340 patent/WO2009105435A1/en not_active Ceased
- 2009-02-19 TW TW098105199A patent/TW200948791A/zh unknown
-
2010
- 2010-07-26 ZA ZA2010/05314A patent/ZA201005314B/en unknown
- 2010-07-28 CR CR11604A patent/CR11604A/es not_active Application Discontinuation
- 2010-07-29 NI NI201000132A patent/NI201000132A/es unknown
- 2010-08-06 US US12/852,076 patent/US8268828B2/en active Active
- 2010-08-12 IL IL207597A patent/IL207597A0/en unknown
- 2010-08-18 DO DO2010000254A patent/DOP2010000254A/es unknown
- 2010-08-18 SV SV2010003648A patent/SV2010003648A/es not_active Application Discontinuation
- 2010-08-18 EC EC2010010409A patent/ECSP10010409A/es unknown
- 2010-08-19 CO CO10102315A patent/CO6241113A2/es not_active Application Discontinuation
- 2010-09-13 MA MA33173A patent/MA32191B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011512412A (ja) | 2011-04-21 |
| US8268828B2 (en) | 2012-09-18 |
| SV2010003648A (es) | 2011-01-31 |
| IL207597A0 (en) | 2010-12-30 |
| TW200948791A (en) | 2009-12-01 |
| NZ587380A (en) | 2011-09-30 |
| MA32191B1 (fr) | 2011-04-01 |
| MX2010008397A (es) | 2010-08-23 |
| US20100305088A1 (en) | 2010-12-02 |
| ECSP10010409A (es) | 2010-09-30 |
| CO6241113A2 (es) | 2011-01-20 |
| ZA201005314B (en) | 2011-03-30 |
| CR11604A (es) | 2010-10-05 |
| BRPI0908815A2 (pt) | 2019-09-24 |
| CA2715557A1 (en) | 2009-08-27 |
| EP2262784B1 (en) | 2014-04-16 |
| AU2009215643A1 (en) | 2009-08-27 |
| RU2010138577A (ru) | 2012-03-27 |
| KR20100123835A (ko) | 2010-11-25 |
| WO2009105435A1 (en) | 2009-08-27 |
| EP2262784A1 (en) | 2010-12-22 |
| NI201000132A (es) | 2011-03-16 |
| DOP2010000254A (es) | 2010-08-31 |
| PE20091576A1 (es) | 2009-11-05 |
| CL2009000368A1 (es) | 2009-06-26 |
| CN102007108A (zh) | 2011-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070430A1 (es) | Inhibidores del receptor de quimioquinas cxcr3 | |
| CY1124085T1 (el) | Κρυσταλλικα αλατα (s)-6-((1-ακετυλπιπεριδιν-4-υλ)αμινο)-ν-(3-(3,4-διυδροϊσοκινολιν-2(1η)-υλ)-2-υδροξυπροπυλ)πυριμιδινο-4-καρβοξαμιδιου | |
| PE20160751A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| JO3215B1 (ar) | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy | |
| UY33606A (es) | DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC | |
| PE20140934A1 (es) | Derivados de pirazol | |
| MX2013005535A (es) | Compuesto de 3- (amino-aril) -piridina. | |
| UA112317C2 (uk) | Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину | |
| AR067674A1 (es) | Derivados de pirazol utiles para el tratamiento con un antagonista de receptor ccr2 | |
| AR060593A1 (es) | 5-amido-2-carboxiamida-indoles | |
| CR20130145A (es) | Moduladores del receptor gpr119 y el tratamieto de trastornos relacionados con este | |
| RU2010116821A (ru) | N-гетероциклические биарильные карбоксамиды в качестве антагонистов рецептора ccr | |
| CY1113715T1 (el) | Αναλογα πυριδονης και πυριδαζονης ως ρυθμιστες toy gpr119 | |
| PE20110875A1 (es) | Derivados de isoindol como inhibidores de bace | |
| AR049696A1 (es) | Derivados de indol | |
| CO7131360A2 (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
| MX353209B (es) | Antagonistas d2, metodos de sintesis y metodos de uso. | |
| ATE475645T1 (de) | Pyrrolidinderivate als doppelte nk1/nk3- rezeptorenantagonisten | |
| PE20161378A1 (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y transtornos relacionados | |
| EA201200602A1 (ru) | Индазолы и пиразолопиридины в качестве антагонистов рецептора ccr1 | |
| RU2016149804A (ru) | Производные бензолсульфонамида и их применение в качестве модуляторов орфанного рецептора y, связанного с ретиноевой кислотой | |
| AR076692A1 (es) | Piperidinas sustituidas | |
| AR056883A1 (es) | Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |